Global Benign Prostatic Hyperplasia Clinical Pipeline Insight 2018″ report provides a comprehensive analysis of BPH profiles currently undergoing clinical trials. The in-depth clinical insight presented in the report helps the reader to analyse and identify the various stakeholders involved in the clinical development and commercialization of BPH drugs in the global market. Also, the company profile section provides details such as company overview, business strategies, product portfolio, and recent developments.

Benign Prostatic Hyperplasia (also called benign prostatic hyperplasia or prostate gland enlargement, abbreviated as BPH) is non-malignant (noncancerous) enlargement of the prostate gland (small organ that lies below the bladder and surrounds the urethra in male). The prostate makes a fluid that helps to nourish sperm as part of the semen.

Prevalence of the disease increase with increase in the age of men. BPH is extremely common and develops in men above 50. It is symptomized by increased frequency of urination, dribbling at end of urination and weak urine stream followed by damage to kidneys. Treatment options include medications and surgery based on the severity of the disease.

BPH market has been growing at a steady rate. There are many prescription drugs and generics available for the treatment of BPH. Companies like Pfizer, Abbott, Sanofi, Mylan, Workhardt are commercializing the generics drugs for BPH globally. Emphasis on products targeted for the unmet needs of the aging population or the complications associated with surgical procedures has gained the focus of R&D for the disease. This report helps the reader to identify key players. 432 clinical studies are ongoing as per ct.gov. of these approximately 24 studies have been suspended or terminated.

Some of the key players in the market include GSK, Astellas, Sanofi, Abbvie, Actavis, Allergan, BI, Daiichi, Eli Lilly, Merck, Mylan, Pfizer, ProArc Medical, BTG International, Transition Therapeutics etc. are developing late stage, Phase 2, Phase 1, early stage (includes preclinical, discovery/research) molecules for BPH. This report also includes discontinued/suspended and clinical unknown phase products along with their mechanism of action, route of administration, and molecule type.